Amylyx CMO sells 10K shares for tax withholding

Amylyx’s Chief Medical Officer reported automatic share sales tied to tax withholding on vested performance stock units.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Medical Officer Camille L. Bedrosian sold a total of 10,028 shares of common stock on September 10, 2026. The transactions were made to cover tax withholding obligations arising from the vesting of performance stock units and were described as automatic and not at her discretion. The sales included 7,947 shares at a weighted average price of $32.21 (with individual trades between $31.76 and $32.68) and 2,081 shares at a weighted average price of $33.09 (with trades between $32.85 and $33.29).

Insider Trade Summary

Net Seller: 10,028 shares

Net Sell 2 txns

Insider Bedrosian Camille L

Role Chief Medical Officer

Sold 10,028 shs ($325K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	7,947	$32.2139	$256K
Sale	Common Stock F1, F3	2,081	$33.0919	$69K

Holdings After Transaction: Common Stock — 278,064 shares (Direct)

Footnotes (3)

1. F1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.76 to $32.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.85 to $33.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Key Figures

Shares sold (first transaction): 7,947 shares Weighted average price (first transaction): $32.21 per share Shares sold (second transaction): 2,081 shares +2 more

5 metrics

Shares sold (first transaction) 7,947 shares Common stock sold on September 10, 2026, to cover tax withholding

Weighted average price (first transaction) $32.21 per share Trades ranged from $31.76 to $32.68

Shares sold (second transaction) 2,081 shares Common stock sold on September 10, 2026, to cover tax withholding

Weighted average price (second transaction) $33.09 per share Trades ranged from $32.85 to $33.29

Total shares sold 10,028 shares Aggregate shares sold across both transactions on September 10, 2026

Key Terms

performance stock units, tax withholding obligations, weighted average price

3 terms

performance stock units financial

"in connection with the vesting of performance stock units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

tax withholding obligations financial

"to cover tax withholding obligations in connection with the vesting"

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AMLX report for Camille L. Bedrosian?

Amylyx reported that Chief Medical Officer Camille L. Bedrosian sold 10,028 shares of common stock on September 10, 2026, in automatic transactions to cover tax withholding obligations related to the vesting of performance stock units.

How many AMLX shares were sold in each transaction?

Two transactions were reported: one for 7,947 shares and another for 2,081 shares of Amylyx common stock, all on September 10, 2026, associated with tax withholding on vested performance stock units.

What prices were received in the AMLX insider sales?

The 7,947 shares were sold at a weighted average price of $32.21, with prices ranging from $31.76 to $32.68. The 2,081 shares were sold at a weighted average price of $33.09, with prices ranging from $32.85 to $33.29.

Were the AMLX insider share sales discretionary?

No. The filing states the shares were required to be sold to cover tax withholding obligations upon vesting of performance stock units, and that these sales were automatic and not at the discretion of Camille L. Bedrosian.

Were the AMLX insider transactions under a Rule 10b5-1 plan?

The document-level Rule 10b5-1 checkbox is not affirmatively marked for these transactions, and the footnotes instead describe the sales as automatic tax-withholding sales related to vested performance stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:01 PM Accepted by SEC EDGAR 09/14/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bedrosian Camille L

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		S(1)		7,947	D	$32.2139(2)	280,145	D
Common Stock	09/10/2026		S(1)		2,081	D	$33.0919(3)	278,064	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.76 to $32.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.85 to $33.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen, as Attorney in Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)